Citius Pharmaceuticals, Inc. (CTXR) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$37.4M, or -$3.38 per diluted share. Operating activities generated -$26.6M of cash. At fiscal year end, Citius Pharmaceuticals held $130.9M in total assets against $53.4M in total liabilities, including $4.3M of cash and equivalents.
Open the full interactive Citius Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Citius Pharmaceuticals Key Stats
| Share Price | $0.48 |
|---|---|
| Market Cap | $12.5M |
| 52-Week Range | $0.48 – $1.82 |
| Shares Outstanding | 26.2 million (basic, 2026 Q3) |
Citius Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Operating Income | -$17.7M | -$23.5M | -$33.3M | -$36.7M | -$42.0M | -$38.5M |
| Pre-Tax Income | -$17.5M | -$23.1M | -$33.1M | -$32.0M | -$38.8M | -$38.7M |
| Income Tax | — | $1,233 | $576,000 | $576,000 | $576,000 | $1.1M |
| Net Income | -$17.5M | -$23.1M | -$33.6M | -$32.5M | -$39.1M | -$37.4M |
| Diluted EPS | -$11.25 | -$5.75 | -$5.75 | -$5.38 | -$5.97 | -$3.38 |
Citius Pharmaceuticals Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | — | $3.9M | $1.7M | $1.5M |
| Net Income | -$7.4M | -$8.2M | -$21.2M | -$8.9M |
| Diluted EPS | -$0.67 | -$0.38 | -$0.95 | -$0.34 |
Citius Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.9M | $70.1M | $41.7M | $26.5M | $3.3M | $4.3M |
| Current Assets | $14.0M | $72.8M | $44.6M | $34.4M | $14.2M | $27.9M |
| Total Assets | $43.8M | $142.4M | $114.0M | $103.6M | $116.7M | $130.9M |
| Current Liabilities | $4.1M | $4.0M | $4.5M | $5.8M | $35.8M | $44.9M |
| Total Long-Term Debt | $337,553 | — | — | — | — | — |
| Total Liabilities | $10.1M | $9.6M | $10.6M | $12.2M | $42.5M | $53.4M |
| Shareholders' Equity | $33.7M | $132.2M | $102.8M | $90.8M | $70.1M | $67.6M |
Citius Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$16.9M | -$24.3M | -$28.4M | -$29.1M | -$28.2M | -$26.6M |
| Cash From Investing | -$1,831 | -$40.0M | — | — | -$5.0M | -$5.8M |
| Cash From Financing | $22.9M | $120.5M | — | $13.8M | $10.0M | $33.3M |
| Free Cash Flow | -$16.9M | -$24.3M | -$28.4M | — | — | — |
Figures from Citius Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Citius Pharmaceuticals financials page for every line item.
Citius Pharmaceuticals Company Profile
| Ticker | CTXR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cranford, New Jersey |
| Incorporated in | Nevada |
| Fiscal Year End | September 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001506251 |
Frequently Asked Questions
What was Citius Pharmaceuticals' net income in fiscal 2025?
Citius Pharmaceuticals reported net income of -$37.4M for fiscal 2025.
What was Citius Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Citius Pharmaceuticals' diluted EPS was -$3.38 for fiscal 2025 (adjusted for any later stock splits).
What was Citius Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q3), Citius Pharmaceuticals reported revenue of $1.5M.
How many shares of Citius Pharmaceuticals are outstanding?
Citius Pharmaceuticals reported a weighted average of 26.2 million basic shares outstanding in 2026 Q3.
What is Citius Pharmaceuticals' market cap?
Based on its latest closing price, Citius Pharmaceuticals (CTXR) has a market capitalization of about $12.5M.
When does Citius Pharmaceuticals' fiscal year end?
Citius Pharmaceuticals' fiscal year end, as registered with the SEC, is September 30.
Where is Citius Pharmaceuticals headquartered?
Citius Pharmaceuticals lists its business address in Cranford, New Jersey in its SEC filings.